Mutagenesis Advance Access originally published online on May 17, 2005
Mutagenesis 2005 20(4):271-277; doi:10.1093/mutage/gei037
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Detecting DNA repair capacity of peripheral lymphocytes from cancer patients with UVC challenge test and bleomycin challenge test
1Institute of Occupational and Environmental Institute, Medical College, Zhejiang University, 353 Yan An road, Hangzhou 310006, Zhejiang, People's Republic of China and 2Medical College of Jiaxing University, Jiaxing, 314001, Zhejiang, People's Republic of China
The objective of this study was to evaluate DNA repair capacity of cancer patients with the bleomycin (BLM) challenge test and the UVC challenge test. The human peripheral lymphocytes were collected from 33 patients with different kinds of cancers and 33 controls in the same hospital. The lymphocytes of each subject were divided into two groups: (1) In the BLM challenge test, the lymphocytes were treated with BLM (20 µgml–1) for 30 min, and repaired for 15 min. The DNA damage before and after BLM exposure was detected with comet assay to assess DNA repair capacity. (2) In the UVC challenge test, the lymphocytes were exposed to UVC (254 nm) at the dose of 1.5 Jm–2. DNA damage of lymphocytes was measured before UVC exposure and at 90 and 240 min after UVC exposure using comet assay, then DNA repair percentage (DRP) was calculated. The results of this study indicate that the average DRPs of cancer patients were 75.63 ± 3.11 and 68.98 ± 4.19% calculated with tail length (TL) and tail moment (TM), respectively, in the BLM challenge test, which were significantly lower than those (91.11 ± 1.09 and 88.19 ± 1.71%) of controls (P < 0.01). Also, the mean DRPs of cancer patients were 49.19 ± 3.47 and 58.27 ± 3.64% calculated with TL and TM, respectively, in the UVC test, which were significantly lower than those (77.52 ± 2.06 and 83.12 ± 2.36%) of controls (P < 0.01). The correlation between the DRPs (%) drawn with TL and TM in the BLM test or between the DRPs (%) drawn with mean TL and mean TM in the UVC challenge test were significant (P < 0.05). The DNA repair capacity measured with the BLM and UVC challenge tests in 33 cancer patients was significantly lower than that in controls.
* To whom correspondence should be addressed. Tel: +86 571 87217188; Fax: +86 571 86996525; Email: he_jiliang{at}hotmail.com
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  D. J. McKenna, S. R. McKeown, and V. J. McKelvey-Martin Potential use of the comet assay in the clinical management of cancer Mutagenesis, May 1, 2008; 23(3): 183 - 190. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Thyagarajan, K. E. Anderson, C. J. Lessard, G. Veltri, D. R. Jacobs, A. R. Folsom, and M. D. Gross Alkaline unwinding flow cytometry assay to measure nucleotide excision repair Mutagenesis, March 1, 2007; 22(2): 147 - 153. [Abstract] [Full Text] [PDF]
|
|